Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features

Background Barrett's esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic surveillance in Barrett's esophagus has been debated because of the low incidence of esophageal adenocarcinoma in Barrett's esophagus. Moreover, high inter-observer and sampling-dependent variation in the histologic staging of dysplasia make clinical risk assessment problematic. In this study, we developed a 3-tiered risk stratification strategy, based on systematically selected epigenetic and clinical parameters, to improve Barrett's esophagus surveillance efficiency. Methods and Findings We defined high-grade dysplasia as endpoint of progression, and Barrett's esophagus progressor patients as Barrett's esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. We analyzed 4 epigenetic and 3 clinical parameters in 118 Barrett's esophagus tissues obtained from 35 progressor and 27 non-progressor Barrett's esophagus patients from Baltimore Veterans Affairs Maryland Health Care Systems and Mayo Clinic. Based on 2-year and 4-year prediction models using linear discriminant analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), Barrett's esophagus specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. This 3-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model. Progression-free survivals differed significantly among the 3 risk groups, with p = 0.0022 (HR vs. IR) and p<0.0001 (HR or IR vs. LR). Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy. Conclusions This 3-tiered risk stratification strategy has the potential to exert a profound impact on Barrett's esophagus surveillance accuracy and efficiency.

[1]  M. Johnston,et al.  Technology insight: ablative techniques for Barrett's esophagus--current and emerging trends. , 2005, Nature clinical practice. Oncology.

[2]  Noel S Weiss,et al.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study. , 2002, Gastroenterology.

[3]  Segment length and risk for neoplastic progression in patients with Barrett esophagus. , 2000, Annals of internal medicine.

[4]  O. Cummings,et al.  Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. , 1999, Gastrointestinal endoscopy.

[5]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[6]  K Abrams,et al.  Inter‐observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis , 2001, The Journal of pathology.

[7]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[8]  H. Barr.  Protagonist: endoscopic surveillance of patients with Barrett's oesophagus. , 2002, Gut.

[9]  Yutaka Shimada,et al.  Prediction of survival in patients with esophageal carcinoma using artificial neural networks , 2005, Cancer.

[10]  P. Jones,et al.  Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. , 1997, Carcinogenesis.

[11]  B. Overholt,et al.  What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis , 2003, Gut.

[12]  M. Rugge,et al.  Gastric dysplasia: the Padova international classification. , 2000, The American journal of surgical pathology.

[13]  R. Cestari,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.

[14]  B. Iacopetta,et al.  Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands , 2002, Gut.

[15]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Carissa A. Sanchez,et al.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression , 2001, American Journal of Gastroenterology.

[17]  S. Ishiguro,et al.  Patient Presentation and Pathologic Diagnosis of Superficial Carcinoma of the Esophagus: High-Grade Dysplasia and Mucosal Carcinoma from the Japanese Standpoint , 2002 .

[18]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[19]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[20]  A. Schned,et al.  The Development of Dysplasia and Adenocarcinoma During Endoscopic Surveillance of Barrett's Esophagus , 1998, American Journal of Gastroenterology.

[21]  M. Imamura.  Superficial Esophageal Neoplasm , 2012, Springer Japan.

[22]  J. Goldblum,et al.  The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression , 2000, American Journal of Gastroenterology.

[23]  Suna Wang,et al.  Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. , 2002, Cancer research.

[24]  T. Demeester,et al.  Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment. , 1996, Digestive diseases.

[25]  Patricia L. Blount,et al.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables , 2001, American Journal of Gastroenterology.

[26]  Michael Vieth,et al.  Prevalence of Barrett's esophagus in the general population: an endoscopic study. , 2005, Gastroenterology.

[27]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[28]  G. Lapertosa,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. A prospective study , 2000 .

[29]  Patricia L. Blount,et al.  Extent of Low-Grade Dysplasia Is a Risk Factor for the Development of Esophageal Adenocarcinoma in Barrett's Esophagus , 2007, The American Journal of Gastroenterology.

[30]  R. Arceci.  CpG Island Methylator Phenotype Is a Strong Determinant of Poor Prognosis in NeuroblastomasAbe M, Ohira M, Kaneda A, et al (Natl Cancer Ctr Research Inst, Tokyo; Univ of Tokyo; Chiba Cancer Ctr Research Inst, Japan) Cancer Res 65:828-834, 2005§ , 2006 .

[31]  F. Ellis,et al.  Endoscopic surveillance of Barrett's esophagus. Does it help? , 1993, The Journal of thoracic and cardiovascular surgery.

[32]  E. Montgomery,et al.  Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. , 2001, Human pathology.

[33]  P. Laird,et al.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. , 2000, Cancer research.

[34]  John J Vargo,et al.  Complications of upper GI endoscopy. , 2002, Gastrointestinal endoscopy.

[35]  H. Barr,et al.  Endoscopic surveillance of patients with Barrett’s oesophagus , 2002, Gut.

[36]  A. Weston,et al.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma , 1999, American Journal of Gastroenterology.

[37]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[38]  S. Toyooka,et al.  Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. , 2002, Cancer research.

[39]  A. Cameron,et al.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. , 1997, The American journal of gastroenterology.

[40]  M. Pepe,et al.  Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk , 2005, Oncogene.

[41]  S. Spechler,et al.  Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.

[42]  A. Tannapfel.  Molecular Findings in Barrett’s Epithelium , 2004, Digestive Diseases.

[43]  E. Hudson,et al.  Advances in Brief Microsatellite Instability Occurs Frequently and in Both Diploid and Aneuploid Cell Populations of Barrett ' s-associated Esophageal Adenocarcinomas ' , 2006 .

[44]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[45]  R. Playford.  Endoscopic surveillance of patients with Barrett’s oesophagus , 2002, Gut.

[46]  Fumiaki Sato,et al.  CpG island hypermethylation in progression of esophageal and gastric cancer , 2006, Cancer.

[47]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[48]  R. Wong,et al.  Barrett's esophagus and risk of esophageal adenocarcinoma. , 2003, Seminars in gastrointestinal disease.

[49]  F. Bazzoli,et al.  Endoscopic surveillance in Barrett's esophagus. , 2002, Minerva gastroenterologica e dietologica.